THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC
WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT
KRAS PATIENTS

J 2020

THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS

SEHNALOVÁ, Irena, Barbora ŘÍHOVÁ, Radim NĚMEČEK, Kateřina KINTROVÁ, Regina DEMLOVÁ et. al.

Základní údaje

Originální název

THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS

Autoři

SEHNALOVÁ, Irena (203 Česká republika, domácí), Barbora ŘÍHOVÁ (203 Česká republika, garant, domácí), Radim NĚMEČEK (203 Česká republika), Kateřina KINTROVÁ (203 Česká republika, domácí) a Regina DEMLOVÁ (203 Česká republika, domácí)

Vydání

FARMACIA, BUCURESTI, SOC STIINTE FARMACEUTICE ROMANIA, 2020, 0014-8237

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Rumunsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.433

Kód RIV

RIV/00216224:14110/20:00116168

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.31925/farmacia.2020.3.25

UT WoS

000543326400025

Klíčová slova anglicky

bevacizumab; cetuximab; panitumumab; colorectal cancer; cost analysis

Štítky

14110516, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 20. 5. 2022 07:48, Mgr. Tereza Miškechová

Anotace

V originále

Targeted monoclonal antibodies bevacizumab, cetuximab and panitumumab are reimbursed in the Czech Republic in combination with chemotherapy or alone in metastatic colorectal cancer (mCRC). However, the high cost is a potentially limiting factor. The real-world costs and effectiveness of first line bevacizumab followed by cetuximab or panitumumab (EGFRi) were retrospectively assessed from the perspective of healthcare payer. Total 71 WT KRAS patients (56% men; median age 60.5 years) were evaluated between April 2007 and May 2017. During our follow-up period (30 months on average) 55% patients died. The mean cost to PD was EUR 32,107 and EUR 24,510 in bevacizumab and EGFRi treatment respectively with median PFS 9.7 and 5.0 months. The median overall survival was 27.2 months and the mean cost from sequential therapy initiation to death was EUR 63,682. The targeted therapy made up 77%, 86% and 76% of the costs in the first line, second line and from the initiation of sequential therapy to death respectively.

Návaznosti

LM2018128, projekt VaV

Název: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Akronym: CZECRIN)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Český národní uzel Evropské sítě infrastruktur klinického výzkumu (CZECRIN)

Citovat

SEHNALOVÁ, Irena, Barbora ŘÍHOVÁ, Radim NĚMEČEK, Kateřina KINTROVÁ a Regina DEMLOVÁ. THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS. FARMACIA. BUCURESTI: SOC STIINTE FARMACEUTICE ROMANIA, 2020, roč. 68, č. 3, s. 572-578. ISSN 0014-8237. Dostupné z: https://dx.doi.org/10.31925/farmacia.2020.3.25.

@article{1673750,
   author = {Sehnalová, Irena and Říhová, Barbora and Němeček, Radim and Kintrová, Kateřina and Demlová, Regina},
   article_location = {BUCURESTI},
   article_number = {3},
   doi = {http://dx.doi.org/10.31925/farmacia.2020.3.25},
   keywords = {bevacizumab; cetuximab; panitumumab; colorectal cancer; cost analysis},
   language = {eng},
   issn = {0014-8237},
   journal = {FARMACIA},
   title = {THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS},
   url = {http://farmaciajournal.com/wp-content/uploads/2020-03-art-25-Sehnalova_Rihova_Demlova_Cehia_572-578.pdf},
   volume = {68},
   year = {2020}
}

TY  - JOUR
ID  - 1673750
AU  - Sehnalová, Irena - Říhová, Barbora - Němeček, Radim - Kintrová, Kateřina - Demlová, Regina
PY  - 2020
TI  - THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS
JF  - FARMACIA
VL  - 68
IS  - 3
SP  - 572-578
EP  - 572-578
PB  - SOC STIINTE FARMACEUTICE ROMANIA
SN  - 00148237
KW  - bevacizumab
KW  - cetuximab
KW  - panitumumab
KW  - colorectal cancer
KW  - cost analysis
UR  - http://farmaciajournal.com/wp-content/uploads/2020-03-art-25-Sehnalova_Rihova_Demlova_Cehia_572-578.pdf
L2  - http://farmaciajournal.com/wp-content/uploads/2020-03-art-25-Sehnalova_Rihova_Demlova_Cehia_572-578.pdf
N2  - Targeted monoclonal antibodies bevacizumab, cetuximab and panitumumab are reimbursed in the Czech Republic in combination with chemotherapy or alone in metastatic colorectal cancer (mCRC). However, the high cost is a potentially limiting factor. The real-world costs and effectiveness of first line bevacizumab followed by cetuximab or panitumumab (EGFRi) were retrospectively assessed from the perspective of healthcare payer. Total 71 WT KRAS patients (56% men; median age 60.5 years) were evaluated between April 2007 and May 2017. During our follow-up period (30 months on average) 55% patients died. The mean cost to PD was EUR 32,107 and EUR 24,510 in bevacizumab and EGFRi treatment respectively with median PFS 9.7 and 5.0 months. The median overall survival was 27.2 months and the mean cost from sequential therapy initiation to death was EUR 63,682. The targeted therapy made up 77%, 86% and 76% of the costs in the first line, second line and from the initiation of sequential therapy to death respectively.
ER  -

SEHNALOVÁ, Irena, Barbora ŘÍHOVÁ, Radim NĚMEČEK, Kateřina KINTROVÁ a Regina DEMLOVÁ. THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS. \textit{FARMACIA}. BUCURESTI: SOC STIINTE FARMACEUTICE ROMANIA, 2020, roč.~68, č.~3, s.~572-578. ISSN~0014-8237. Dostupné z: https://dx.doi.org/10.31925/farmacia.2020.3.25.

Podrobný výpis o publikaci